Figures & data
Table 1 Odds ratios for efficacy and withdrawal, numbers needed to treat (NNT) and numbers needed to harm (NNH)
Figure 1 Efficacy analysis of drugs used for painful diabetic neuropathy.
![Figure 1 Efficacy analysis of drugs used for painful diabetic neuropathy.](/cms/asset/79b6616f-12f3-4120-94a7-1f4d108ab85a/dmso_a_24825_f0001_c.jpg)
Table 2 Summary of American Academy of Neurology recommendations
Table 3 Treatment options for symptomatic diabetic polyneuropathy pain dosing and side effects
Table 4 Treatment algorithm for painful diabetic peripheral neuropathy (Toronto Consensus Panel on Diabetic Neuropathy)
Table 5 Tailoring treatment to the patient (Toronto Consensus Panel on Diabetic Neuropathy)
Figure 2 Changes in SF-36 domain scores grouped according to extent of pain relief in patients treated with pregabalin.
![Figure 2 Changes in SF-36 domain scores grouped according to extent of pain relief in patients treated with pregabalin.](/cms/asset/7ff2ccbe-9162-40f6-986d-c16269ab003d/dmso_a_24825_f0002_c.jpg)
Figure 3 Mediational analysis model, illustrating that the change in SF-36 domain score (overall treatment effect) may be due to a direct effect of pregabalin on that particular SF-36 domain (direct effect) or may be mediated through pregabalin-driven pain relief or improvements in sleep (indirect effects).
![Figure 3 Mediational analysis model, illustrating that the change in SF-36 domain score (overall treatment effect) may be due to a direct effect of pregabalin on that particular SF-36 domain (direct effect) or may be mediated through pregabalin-driven pain relief or improvements in sleep (indirect effects).](/cms/asset/2b2a6971-bebc-416c-813e-108034962675/dmso_a_24825_f0003_b.jpg)
Figure 4 Treatment algorithm: neuropathic pain after exclusion of non-diabetic etiologies and stabilization of glycemic control.
Abbreviations: IVIg, intravenous immunoglobulin; SNRI, serotonin-noradrenaline reuptake inhibitors; TCA, tricyclic antidepressants.
![Figure 4 Treatment algorithm: neuropathic pain after exclusion of non-diabetic etiologies and stabilization of glycemic control.](/cms/asset/3d3de7b8-ff8e-4ab2-ad9c-31fdb197bf3d/dmso_a_24825_f0004_c.jpg)